BHVN

Biohaven Ltd.

Tremor tracks 1 of its cancer trials.

Company-wide warning signs

These add points to every one of this company's trials.

A key executive is leavingSince Jul 9, 2026+3.8

Trials

BHVNBiohaven Therapeutics Ltd.
4Calm
A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors
Signing up patientsPhase 1/2500 patientsMain results: Feb 2028

Key executives leaving

From the last 12 months of the company's SEC reports.

Jul 9, 2026
“Car will retire as Chief Scientific Officer of the Company and will remain with the Company as a part-time employee in the newly created role of Chief Innovation Officer.”
Read the filing ↗

Insider trades (last 6 months)

“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.

0 sales (0 not pre-planned) · 0 purchases

No insider sales or purchases in the last 6 months.

Recent SEC filings

Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.

Money left

Coming soon: how many months of cash the company has, from its quarterly reports.